|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Almeeri MNE, Awies M and Constantinou C:
Prostate cancer, pathophysiology and recent developments in
management: A narrative review. Curr Oncol Rep. 26:1511–1519. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wasim S, Lee SY and Kim J: Complexities of
prostate cancer. Int J Mol Sci. 23:142572022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perler BK, Friedman ES and Wu GD: The role
of the gut microbiota in the relationship between diet and human
health. Annu Rev Physiol. 85:449–468. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang MY, Sang LX and Sun SY: Gut
microbiota and female health. World J Gastroenterol. 30:1655–1662.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matijašić M, Meštrović T, Paljetak HC,
Perić M, Barešić A and Verbanac D: Gut microbiota beyond
bacteria-mycobiome, virome, archaeome, and eukaryotic parasites in
IBD. Int J Mol Sci. 21:26682020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pant A, Maiti TK, Mahajan D and Das B:
Human gut microbiota and drug metabolism. Microb Ecol. 86:97–111.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang Q, Wang B, Zheng Q, Li H, Meng X,
Zhou F and Zhang L: A review of gut microbiota-derived metabolites
in tumor progression and cancer therapy. Adv Sci (Weinh).
10:e22073662023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aburto MR and Cryan JF: Gastrointestinal
and brain barriers: unlocking gates of communication across the
microbiota-gut-brain axis. Nat Rev Gastroenterol Hepatol.
21:222–247. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu CL and Schnabl B: The gut-liver axis
and gut microbiota in health and liver disease. Nat Rev Microbiol.
21:719–733. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pernigoni N, Guo C, Gallagher L, Yuan W,
Colucci M, Troiani M, Liu L, Maraccani L, Guccini I, Migliorini D,
et al: The potential role of the microbiota in prostate cancer
pathogenesis and treatment. Nat Rev Urol. 20:706–718. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gut microbiota differs significantly
between men with and without prostate cancer. Cancer. 129:169–170.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kalinen S, Kallonen T, Gunell M, Ettala O,
Jambor I, Knaapila J, Syvänen KT, Taimen P, Poutanen M, Aronen HJ,
et al: Differences in gut microbiota profiles and microbiota
steroid hormone biosynthesis in men with and without prostate
cancer. Eur Urol Open Sci. 62:140–150. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zha C, Peng Z, Huang K, Tang K, Wang Q,
Zhu L, Che B, Li W, Xu S, Huang T, et al: Potential role of gut
microbiota in prostate cancer: Immunity, metabolites, pathways of
action? Front Oncol. 13:11962172023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Porter CM, Shrestha E, Peiffer LB and
Sfanos KS: The microbiome in prostate inflammation and prostate
cancer. Prostate Cancer Prostatic Dis. 21:345–354. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cereda V, Falbo PT, Manna G, Iannace A,
Menghi A, Corona M, Semenova D, Calò L, Carnevale R, Frati G and
Lanzetta G: Hormonal prostate cancer therapies and cardiovascular
disease: A systematic review. Heart Fail Rev. 27:119–134. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Beam A, Clinger E and Hao L: Effect of
diet and dietary components on the composition of the gut
microbiota. Nutrients. 13:27952021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
García-Montero C, Fraile-Martínez O,
Gómez-Lahoz AM, Pekarek L, Castellanos AJ, Noguerales-Fraguas F,
Coca S, Guijarro LG, García-Honduvilla N, Asúnsolo A, et al:
Nutritional components in western diet versus mediterranean diet at
the gut microbiota-immune system interplay. implications for health
and disease. Nutrients. 13:6992021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pei X, Liu L and Han Y: Advances in human
microbiome and prostate cancer research. Front Immunol.
16:15766792025. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sha S, Ni L, Stefil M, Dixon M and
Mouraviev V: The human gastrointestinal microbiota and prostate
cancer development and treatment. Investig Clin Urol. 61 (Suppl
1):S43–S50. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Han EJ, Ahn JS, Choi YJ, Kim DH, Choi JS
and Chung HJ: Exploring the gut microbiome: A potential biomarker
for cancer diagnosis, prognosis, and therapy. Biochim Biophys Acta
Rev Cancer. 1880:1892512025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ling Z, Liu X, Cheng Y, Yan X and Wu S:
Gut microbiota and aging. Crit Rev Food Sci Nutr. 62:3509–3534.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Adak A and Khan MR: An insight into gut
microbiota and its functionalities. Cell Mol Life Sci. 76:473–493.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Zhou M, Zhou Y and Guan X:
Dietary components regulate chronic diseases through gut
microbiota: A review. J Sci Food Agric. 103:6752–6766. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McCallum G and Tropini C: The gut
microbiota and its biogeography. Nat Rev Microbiol. 22:105–118.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weingarden AR and Vaughn BP: Intestinal
microbiota, fecal microbiota transplantation, and inflammatory
bowel disease. Gut Microbes. 8:238–252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boulangé CL, Neves AL, Chilloux J,
Nicholson JK and Dumas ME: Impact of the gut microbiota on
inflammation, obesity, and metabolic disease. Genome Med. 8:422016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Zhu Y, Guo Q, Wang W and Zhang L:
High-throughput sequencing analysis of the characteristics of the
gut microbiota in aged patients with sarcopenia. Exp Gerontol.
182:1122872023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Zhong H, Li Y, Shi Z, Ren H,
Zhang Z, Zhou X, Tang S, Han X, Lin Y, et al: Sex- and age-related
trajectories of the adult human gut microbiota shared across
populations of different ethnicities. Nat Aging. 1:87–100. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fajstova A, Galanova N, Coufal S, Malkova
J, Kostovcik M, Cermakova M, Pelantova H, Kuzma M, Sediva B,
Hudcovic T, et al: Diet rich in simple sugars promotes
pro-inflammatory response via gut microbiota alteration and TLR4
signaling. Cells. 9:27012020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Francescangeli F, De Angelis ML and Zeuner
A: Dietary factors in the control of gut homeostasis, intestinal
stem cells, and colorectal cancer. Nutrients. 11:29362019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li C and Hu Y: Align resistant starch
structures from plant-based foods with human gut microbiome for
personalized health promotion. Crit Rev Food Sci Nutr.
63:2509–2520. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu Y, Cao Y, Liu P, Zhai S, Liu Y, Tang
X, Lin J, Shi M, Qi D, Deng X, et al: ATF3-induced activation of
NF-κB pathway results in acquired PARP inhibitor resistance in
pancreatic adenocarcinoma. Cell Oncol (Dordr). 47:939–950. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou CB, Zhou YL and Fang JY: Gut
microbiota in cancer immune response and immunotherapy. Trends
Cancer. 7:647–660. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu Q, Yang Y, Pan M, Yang F, Yu Y and
Qian Z: Role of the gut microbiota in tumorigenesis and treatment.
Theranostics. 14:2304–2328. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sivaprakasam S, Prasad PD and Singh N:
Benefits of short-chain fatty acids and their receptors in
inflammation and carcinogenesis. Pharmacol Ther. 164:144–151. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kaźmierczak-Siedlecka K, Marano L, Merola
E, Roviello F and Połom K: Sodium butyrate in both prevention and
supportive treatment of colorectal cancer. Front Cell Infect
Microbiol. 12:10238062022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng WY, Wu CY and Yu J: The role of gut
microbiota in cancer treatment: friend or foe? Gut. 69:1867–1876.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jandhyala SM, Talukdar R, Subramanyam C,
Vuyyuru H, Sasikala M and Nageshwar Reddy D: Role of the normal gut
microbiota. World J Gastroenterol. 21:8787–8803. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu L, Wang H, Chen X, Zhang Y, Zhang H
and Xie P: Gut microbiota and its metabolites in depression: from
pathogenesis to treatment. EBioMedicine. 90:1045272023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Y, Wang X, Ye Y and Ren Q: Gut
microbiota in cancer: Insights on microbial metabolites and
therapeutic strategies. Med Oncol. 41:252023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kang J, Sun M, Chang Y, Chen H, Zhang J,
Liang X and Xiao T: Butyrate ameliorates colorectal cancer through
regulating intestinal microecological disorders. Anticancer Drugs.
34:227–237. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kostic AD, Chun E, Robertson L, Glickman
JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold
GL, et al: Fusobacterium nucleatum potentiates intestinal
tumorigenesis and modulates the tumor-immune microenvironment. Cell
Host Microbe. 14:207–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Caleça T, Ribeiro P, Vitorino M, Menezes
M, Sampaio-Alves M, Mendes AD, Vicente R, Negreiros I, Faria A and
Costa DA: Breast cancer survivors and healthy women: Could gut
microbiota make a difference?-‘biotacancersurvivors’: A
case-control study. Cancers (Basel). 15:5942023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Arnone AA, Wilson AS, Soto-Pantoja DR and
Cook KL: Diet modulates the gut microbiome, metabolism, and mammary
gland inflammation to influence breast cancer risk. Cancer Prev Res
(Phila). 17:415–428. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang L, Zheng YB, Yin S, Li KP, Wang JH,
Bao EH and Zhu PY: Causal relationship between gut microbiota and
prostate cancer contributes to the gut-prostate axis: Insights from
a Mendelian randomization study. Discov Oncol. 15:582024.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ooijevaar RE, Terveer EM, Verspaget HW,
Kuijper EJ and Keller JJ: Clinical application and potential of
fecal microbiota transplantation. Annu Rev Med. 70:335–351. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen D, Wu J, Jin D, Wang B and Cao H:
Fecal microbiota transplantation in cancer management: Current
status and perspectives. Int J Cancer. 145:2021–2031. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yin Z, Liu B, Feng S, He Y, Tang C, Chen
P, Wang X and Wang K: A large genetic causal analysis of the gut
microbiota and urological cancers: A bidirectional mendelian
randomization study. Nutrients. 15:40862023. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Matsushita M, Fujita K, Hatano K, De
Velasco MA, Tsujimura A, Uemura H and Nonomura N: Emerging
relationship between the gut microbiome and prostate cancer. World
J Mens Health. 41:759–768. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fujimoto S, Hatano K, Banno E, Motooka D,
De Velasco MA, Kura Y, Toyoda S, Hashimoto M, Adomi S, Minami T, et
al: Comparative analysis of gut microbiota in hormone-sensitive and
castration-resistant prostate cancer in Japanese men. Cancer Sci.
116:462–469. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shyanti RK, Greggs J, Malik S and Mishra
M: Gut dysbiosis impacts the immune system and promotes prostate
cancer. Immunol Lett. 268:1068832024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Golombos DM, Ayangbesan A, O'Malley P,
Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G,
Huttenhower C and Scherr DS: The role of gut microbiome in the
pathogenesis of prostate cancer: A prospective, pilot study.
Urology. 111:122–128. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu Y and Jiang H: Compositional
differences of gut microbiome in matched hormone-sensitive and
castration-resistant prostate cancer. Transl Androl Urol.
9:1937–1944. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Newton RU, Christophersen CT, Fairman CM,
Hart NH, Taaffe DR, Broadhurst D, Devine A, Chee R, Tang CI, Spry N
and Galvão DA: Does exercise impact gut microbiota composition in
men receiving androgen deprivation therapy for prostate cancer? A
single-blinded, two-armed, randomised controlled trial. BMJ Open.
9:e0248722019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Matsushita M, Fujita K, Motooka D, Hatano
K, Fukae S, Kawamura N, Tomiyama E, Hayashi Y, Banno E, Takao T, et
al: The gut microbiota associated with high-Gleason prostate
cancer. Cancer Sci. 112:3125–3135. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li JKM, Wang LL, Wong CYP, Chiu PKF, Teoh
JYC, Kwok HSW, Leung SCH, Wong SH, Tsui SKW and Ng CF: A
cross-sectional study on gut microbiota in prostate cancer patients
with prostatectomy or androgen deprivation therapy. Prostate Cancer
Prostatic Dis. 24:1063–1072. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Takezawa K, Fujita K, Matsushita M,
Motooka D, Hatano K, Banno E, Shimizu N, Takao T, Takada S, Okada
K, et al: The Firmicutes/Bacteroidetes ratio of the human gut
microbiota is associated with prostate enlargement. Prostate.
81:1287–1293. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Matsushita M, Fujita K, Motooka D, Hatano
K, Hata J, Nishimoto M, Banno E, Takezawa K, Fukuhara S, Kiuchi H,
et al: Firmicutes in gut microbiota correlate with blood
testosterone levels in elderly men. World J Mens Health.
40:517–525. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Fernandes A, Oliveira A, Guedes C,
Fernandes R, Soares R and Barata P: Effect of radium-223 on the gut
microbiota of prostate cancer patients: A pilot case series study.
Curr Issues Mol Biol. 44:4950–4959. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Huang H, Liu Y, Wen Z, Chen C, Wang C, Li
H and Yang X: Gut microbiota in patients with prostate cancer: A
systematic review and meta-analysis. BMC Cancer. 24:2612024.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Smith KS, Frugé AD, van der Pol W, Caston
NE, Morrow CD, Demark-Wahnefried W and Carson TL: Gut microbial
differences in breast and prostate cancer cases from two randomised
controlled trials compared to matched cancer-free controls. Benef
Microbes. 12:239–248. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Reichard CA, Naelitz BD, Wang Z, Jia X, Li
J, Stampfer MJ, Klein EA, Hazen SL and Sharifi N: Gut
microbiome-dependent metabolic pathways and risk of lethal prostate
cancer: Prospective analysis of a PLCO cancer screening trial
cohort. Cancer Epidemiol Biomarkers Prev. 31:192–199. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Alanee S, El-Zawahry A, Dynda D, Dabaja A,
McVary K, Karr M and Braundmeier-Fleming A: A prospective study to
examine the association of the urinary and fecal microbiota with
prostate cancer diagnosis after transrectal biopsy of the prostate
using 16sRNA gene analysis. Prostate. 79:81–87. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hurst R, Meader E, Gihawi A, Rallapalli G,
Clark J, Kay GL, Webb M, Manley K, Curley H, Walker H, et al:
Microbiomes of urine and the prostate are linked to human prostate
cancer risk groups. Eur Urol Oncol. 5:412–419. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li D, Wang P, Wang P, Hu X and Chen F: The
gut microbiota: A treasure for human health. Biotechnol Adv.
34:1210–1224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Liu Y, Yang C, Zhang Z and Jiang H: Gut
microbiota dysbiosis accelerates prostate cancer progression
through increased LPCAT1 expression and enhanced DNA repair
pathways. Front Oncol. 11:6797122021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Matsushita M, Fujita K, Hayashi T, Kayama
H, Motooka D, Hase H, Jingushi K, Yamamichi G, Yumiba S, Tomiyama
E, et al: Gut microbiota-derived short-chain fatty acids promote
prostate cancer growth via IGF1 signaling. Cancer Res.
81:4014–4026. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Pernigoni N, Zagato E, Calcinotto A,
Troiani M, Mestre RP, Calì B, Attanasio G, Troisi J, Minini M,
Mosole S, et al: Commensal bacteria promote endocrine resistance in
prostate cancer through androgen biosynthesis. Science.
374:216–224. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Matsushita M, Fujita K, Hatano K, Hayashi
T, Kayama H, Motooka D, Hase H, Yamamoto A, Uemura T, Yamamichi G,
et al: High-fat diet promotes prostate cancer growth through
histamine signaling. Int J Cancer. 151:623–636. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Biragyn A and Ferrucci L: Gut dysbiosis: A
potential link between increased cancer risk in ageing and
inflammaging. Lancet Oncol. 19:e295–e304. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhong W, Wu K, Long Z, Zhou X, Zhong C,
Wang S, Lai H, Guo Y, Lv D, Lu J and Mao X: Gut dysbiosis promotes
prostate cancer progression and docetaxel resistance via activating
NF-κB-IL6-STAT3 axis. Microbiome. 10:942022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bui NN, Li CY, Wang LY, Chen YA, Kao WH,
Chou LF, Hsieh JT, Lin H and Lai CH: Clostridium scindens
metabolites trigger prostate cancer progression through androgen
receptor signaling. J Microbiol Immunol Infect. 56:246–256. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liu Y, Zhou Q, Ye F, Yang C and Jiang H:
Gut microbiota-derived short-chain fatty acids promote prostate
cancer progression via inducing cancer cell autophagy and M2
macrophage polarization. Neoplasia. 43:1009282023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hsia YJ, Lin ZM, Zhang T and Chou TC:
Butyrate increases methylglyoxal production through regulation of
the JAK2/Stat3/Nrf2/Glo1 pathway in castration-resistant prostate
cancer cells. Oncol Rep. 51:712024. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Xu W, Li Y, Liu L, Xie J, Hu Z, Kuang S,
Fu X, Li B, Sun T, Zhu C, et al: Icaritin-curcumol activates CD8(+)
T cells through regulation of gut microbiota and the DNMT1/IGFBP2
axis to suppress the development of prostate cancer. J Exp Clin
Cancer Res. 43:1492024. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
You X, Qiu J, Li Q, Zhang Q, Sheng W, Cao
Y and Fu W: Astragaloside IV-PESV inhibits prostate cancer tumor
growth by restoring gut microbiota and microbial metabolic
homeostasis via the AGE-RAGE pathway. BMC Cancer. 24:4722024.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yu Y, Li L, Yang Q, Xue J, Wang B, Xie M,
Shangguan W, Zhu Z and Wu P: Akkermansia muciniphila metabolite
inosine inhibits castration resistance in prostate cancer.
Microorganisms. 12:16532024. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Li S, Liu R, Hao X and Liu X: The role of
gut microbiota in prostate cancer progression: A Mendelian
randomization study of immune mediation. Medicine (Baltimore).
103:e388252024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Miya TV, Marima R, Damane BP, Ledet EM and
Dlamini Z: Dissecting microbiome-derived SCFAs in prostate cancer:
Analyzing gut microbiota, racial disparities, and epigenetic
mechanisms. Cancers (Basel). 15:40862023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhang SL, Cheng LS, Zhang ZY, Sun HT and
Li JJ: Untangling determinants of gut microbiota and tumor
immunologic status through a multi-omics approach in colorectal
cancer. Pharmacol Res. 188:1066332023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Legesse Bedada T, Feto TK, Awoke KS,
Garedew AD, Yifat FT and Birri DJ: Probiotics for cancer
alternative prevention and treatment. Biomed Pharmacother.
129:1104092020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Banna GL, Torino F, Marletta F, Santagati
M, Salemi R, Cannarozzo E, Falzone L, Ferraù F and Libra M:
Lactobacillus rhamnosus GG: An overview to explore the rationale of
its use in cancer. Front Pharmacol. 8:6032017. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Kaźmierczak-Siedlecka K,
Skonieczna-Żydecka K, Hupp T, Duchnowska R, Marek-Trzonkowska N and
Połom K: Next-generation probiotics - do they open new therapeutic
strategies for cancer patients? Gut Microbes. 14:20356592022.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yadav MK, Kumari I, Singh B, Sharma KK and
Tiwari SK: Probiotics, prebiotics and synbiotics: Safe options for
next-generation therapeutics. Appl Microbiol Biotechnol.
106:505–521. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Mahdavi M, Laforest-Lapointe I and Massé
E: Preventing colorectal cancer through prebiotics. Microorganisms.
9:13252021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Holscher HD: Dietary fiber and prebiotics
and the gastrointestinal microbiota. Gut Microbes. 8:172–184. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Fernandes MR, Aggarwal P, Costa RGF, Cole
AM and Trinchieri G: Targeting the gut microbiota for cancer
therapy. Nat Rev Cancer. 22:703–722. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Jain MG, Hislop GT, Howe GR and Ghadirian
P: Plant foods, antioxidants, and prostate cancer risk: Findings
from case-control studies in Canada. Nutr Cancer. 34:173–184. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Miller PE, Morey MC, Hartman TJ, Snyder
DC, Sloane R, Cohen HJ and Demark-Wahnefried W: Dietary patterns
differ between urban and rural older, long-term survivors of
breast, prostate, and colorectal cancer and are associated with
body mass index. J Acad Nutr Diet. 112:824–31. 831.e12012.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lachance G, Robitaille K, Laaraj J,
Gevariya N, Varin TV, Feldiorean A, Gaignier F, Julien IB, Xu HW,
Hallal T, et al: The gut microbiome-prostate cancer crosstalk is
modulated by dietary polyunsaturated long-chain fatty acids. Nat
Commun. 15:34312024. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Yadav A, Kaushik M, Tiwari P and Dada R:
From microbes to medicine: Harnessing the gut microbiota to combat
prostate cancer. Microb Cell. 11:187–197. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Liss MA, White JR, Goros M, Gelfond J,
Leach R, Johnson-Pais T, Lai Z, Rourke E, Basler J, Ankerst D and
Shah DP: Metabolic Biosynthesis Pathways Identified from Fecal
Microbiome Associated with Prostate Cancer. Eur Urol. 74:575–582.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Sfanos KS, Markowski MC, Peiffer LB, Ernst
SE, White JR, Pienta KJ, Antonarakis ES and Ross AE: Compositional
differences in gastrointestinal microbiota in prostate cancer
patients treated with androgen axis-targeted therapies. Prostate
Cancer Prostatic Dis. 21:539–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Matzaras R, Nikopoulou A, Protonotariou E
and Christaki E: Gut microbiota modulation and prevention of
dysbiosis as an alternative approach to antimicrobial resistance: A
narrative review. Yale J Biol Med. 95:479–494. 2022.PubMed/NCBI
|
|
96
|
Lv J, Jin S, Zhang Y, Zhou Y, Li M and
Feng N: Equol: A metabolite of gut microbiota with potential
antitumor effects. Gut Pathog. 16:352024. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Daisley BA, Chanyi RM, Abdur-Rashid K, Al
KF, Gibbons S, Chmiel JA, Wilcox H, Reid G, Anderson A, Dewar M, et
al: Abiraterone acetate preferentially enriches for the gut
commensal Akkermansia muciniphila in castrate-resistant prostate
cancer patients. Nat Commun. 11:48222020. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Kim SJ, Park M, Choi A and Yoo S:
Microbiome and prostate cancer: Emerging diagnostic and therapeutic
opportunities. Pharmaceuticals (Basel). 17:1122024. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Duan H, Wang L, Huangfu M and Li H: The
impact of microbiota-derived short-chain fatty acids on macrophage
activities in disease: Mechanisms and therapeutic potentials.
Biomed Pharmacother. 165:1152762023. View Article : Google Scholar : PubMed/NCBI
|
